CD274 and breast cancer: Accordingly, based on the encouraging immunogenicity correlates in HER2+ BC, such as high TILs and high PD-L1 expression, also this group of patients was included in clinical trials designed to determine the efficacy of immune checkpoint inhibition of mixed BC subtype populations.